制药公司Viatris股价在11月7日盘中大涨5.08%,引发市场关注。公司新鲜出炉的第三季度财报成为推动股价上涨的主因。
数据显示,Viatris第三季度营收达37.4亿美元,超过分析师预期的37.1亿美元。公司调整后每股利润为75美分,也高于外界68美分的预期。出色的业绩主要得益于其新推出的仿制药需求强劲,比如哮喘吸入剂Breyna和ADHD(多动症)治疗药Lisdexamfetamine等新产品。
Viatris是2020年由默克和辉瑞旗下业务合并组建而成,在品牌药和仿制药两大领域都有版图。除了新产品销售亮眼,公司传统品牌药如伟哥、Xanax等也保持了稳健增长。本季度,其品牌药业务同比增长2%至23.6亿美元,仿制药业务增长4%至13.8亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.